##1. Success in Hematologic Malignancies and the Barrier of Solid Tumors: Challenges of Antigen Escape and Heterogeneity CAR‑T cell therapies targeting CD19 and BCMA have produced dramatic complete remissions (CR) in patients with advanced leukemia, lymphoma, and multiple myeloma, reshaping the cell‑therapy market paradigm. However, attempts to translate these modalities to solid tumors have been blocked by profound antigen heterogeneity, antigen loss (antigen escape), and on‑target, off‑tumor toxicity that damages normal tissues. Conventional single‑antigen CAR architectures are insufficient to breach the dense tumor microenvironment (TME) characteristic of solid cancers.

##2. Synthetic‑Biology Programming: Emergence of Logic Gates and SynNotch Circuits Researchers have endowed cells with electronic‑circuit‑like logical operations to maximize decision‑making capacity. Logic‑gate (AND, OR, NOT) CAR systems activate only when multiple antigens are present simultaneously (AND) or are inhibited upon recognition of antigens on normal cells (NOT), demonstrating intelligent designs. Notably, SynNotch (Synthetic Notch) circuits are genetically programmed to induce expression of a second CAR receptor only after engagement of a primary antigen, thereby preventing damage to normal tissues at the source and enabling molecular‑level precision targeting of solid tumors.

##3. From Tumor Eradication to Immune Suppression: A Paradigm Shift Toward Autoimmune Diseases The most disruptive evolution of this platform is the repurposing of a cytotoxic weapon for the restoration of immune tolerance in autoimmune disorders. In an early‑phase clinical study (5–18 patients) of systemic lupus erythematosus (SLE), CD19‑CAR‑T cells completely depleted pathogenic B cells and induced durable remission without adjunctive drugs, demonstrating a powerful "immune reset" effect. Furthermore, CAAR‑T (Chimeric Autoantibody Receptor) cells have been engineered to spare normal B cells while selectively eliminating autoreactive clones, and CAR‑Tregs that home to inflamed sites to locally suppress immunity have been developed. These advances have extended beyond lupus to establish precise immune‑control protocols aimed at curing multiple sclerosis, rheumatoid arthritis, and type‑1 diabetes.

##4. From Fixed Cell Therapies to "Programmable Immune Computers" The significance of this research trend lies in redefining the CAR platform from a “simple anticancer agent” to an “in‑vivo genetically programmable immune‑modulation module.” By freely tuning cytotoxic and suppressive signaling, a single cellular platform can dominate both malignant tumors and autoimmune diseases—representing a technical moat. This redefinition will reshape ex‑vivo cell‑engineering regulatory guidelines and serve as a pivotal milestone that can exponentially increase the commercial value of next‑generation, patient‑specific, all‑in‑one cell‑therapy pipelines.